Abstract
Newer multitargeted kinase inhibitors show prolonged overall and progression-free survival in patients with metastatic differentiated and medullary thyroid cancers.
- Title
- New Treatment Options for Metastatic Thyroid Cancer
- Creators
- Rajesh Kunadharaju - and are house officers in the Department of Internal Medicine, and is a professor and chief of hematology/oncology, all at CHI Creighton University Medical Center in Omaha, Nebraska. is a house officer at MacNeal Hospital in Berwyn, Illinois. Dr. Silberstein is also chief of oncology at the VA Nebraska-Western Iowa Healthcare System in OmahaGaurav Goyal - Creighton UniversityAvantika Rudraraju - and are house officers in the Department of Internal Medicine, and is a professor and chief of hematology/oncology, all at CHI Creighton University Medical Center in Omaha, Nebraska. is a house officer at MacNeal Hospital in Berwyn, Illinois. Dr. Silberstein is also chief of oncology at the VA Nebraska-Western Iowa Healthcare System in OmahaPeter T Silberstein - Creighton University
- Publication Details
- Federal practitioner, Vol.32(Suppl 7), pp.21S-26S
- Identifiers
- 991005966023202656
- Academic Unit
- Hematology & Oncology
- Language
- English
- Resource Type
- Journal article